Increasing time between adalimumab injections in IBD patients.
Recruiting
- Conditions
- Crohn's DiseaseUlcerative ColitisInflammatory Bowel DiseaseAdalimumab
- Registration Number
- NL-OMON20310
- Lead Sponsor
- Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 72
Inclusion Criteria
Age 18 or older.
Written informed consent.
Exclusion Criteria
Concomitant corticosteroid usage
Imminent need for IBD-related surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of patients in remission, 24 weeks after dose adjustment of adalimumab
- Secondary Outcome Measures
Name Time Method -Relapse rates in both groups, defined by increase of fecal calprotectin and/or CRP and clinical activity, and subsequently confirmed by endoscopy<br /><br>-Tolerability